{"nctId":"NCT00740246","briefTitle":"Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia","startDateStruct":{"date":"2005-07","type":"ACTUAL"},"conditions":["Anemia"],"count":594,"armGroups":[{"label":"VIT-45 on Day 0, then Placebo on Day 7","type":"EXPERIMENTAL","interventionNames":["Drug: VIT-45","Drug: Placebo"]},{"label":"Placebo on Day 0, then VIT-45 on Day 7","type":"EXPERIMENTAL","interventionNames":["Drug: VIT-45","Drug: Placebo"]}],"interventions":[{"name":"VIT-45","otherNames":["ferric carboxymaltose"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects \\> or = 18 years of age and able to give informed consent\n* Historical laboratory Hgb indicative of anemia within 3 months prior to screening visit\n* Screening Visit laboratory Hgb indicative of anemia\n* Screening Visit ferritin indicative of iron deficiency anemia\n\nExclusion Criteria:\n\n* Known hypersensitivity to VIT-45\n* Previously received VIT-45\n* Parenteral iron in the 4 weeks prior to screening\n* Chronic or serious active infection\n* Malignancy history\n* Aspartate aminotransferase (AST) or Alanine transaminase( ALT) greater than the upper limit of normal\n* Anticipated need for surgery or initiation of dialysis during the study\n* Pregnant or sexually active females who are not willing to use an effective form of birth control","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period","description":"Number of participants with any treatment-emergent adverse events experienced by participants. The 7-day study period for Study Period 1 ended with the initiation of dosing for Study Period 2. The 7-day study period fo Study Period 2 ended with the completion of Day 14 procedures.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":584},"commonTop":["Headache"]}}}